131233-49-3Relevant academic research and scientific papers
Clamping device anthraquinone compound in the preparation of antineoplastic application
-
Paragraph 0043; 0044; 0049, (2019/01/14)
The invention relates to application of dianthraquinonyl, in particular to application of dianthraquinonyl compounds to preparing anti-tumor medicine. Radioactive therapeutic nuclides are labeled on dianthraquinonyl medicine, and accordingly the labeled medicine with excellent tumor targeting can be obtained. The application has the advantages that the compounds can be gathered on dead cells and tissues in tumors and are provided with instable chemical elements or isotopes, accordingly, radiation can occur, surrounding cells and tissues can be destroyed, and the purpose of treating tumors can be achieved.
Synthesis and Evaluation of 131I-Skyrin as a Necrosis Avid Agent for Potential Targeted Radionuclide Therapy of Solid Tumors
Wang, Cong,Jin, Qiaomei,Yang, Shengwei,Zhang, Dongjian,Wang, Qin,Li, Jindian,Song, Shaoli,Sun, Ziping,Ni, Yicheng,Zhang, Jian,Yin, Zhiqi
, p. 180 - 189 (2016/01/15)
An innovative anticancer approach targeted to necrotic tissues, which serves as a noncancerous and generic anchor, may present a breakthrough. Necrosis avid agents with a flat conjugate aromatic structure selectively accumulate in necrotic tissues, but they easily form aggregates that undesirably distribute to normal tissues. In this study, skyrin, a dianthraquinone compound with smaller and distorted -cores and thus decreased aggregates as compared with hypericin (Hyp), was designed to target necrosis for tumor therapy. Aggregation studies of skyrin by UV/vis spectroscopy showed a smaller self-association constant with skyrin than with Hyp. Skyrin was labeled by iodine-131 with a radiochemical purity of 98% and exhibited good stability in rat serum for 72 h. In vitro cell uptake studies showed significant difference in the uptake of 131I-skyrin by necrotic cells compared to normal cells (P 131I-skyrin in necrotic liver and muscle (p 131I-Hyp. In mice bearing H22 tumor xenografts treated with combretastatin A4 disodium phosphate, the highest uptake of 131I-skyrin was found in necrotic tumor. In conclusion, 131I-skyrin appears a promising agent with reduced accumulation in nontarget organs for targeted radionuclide therapy of solid tumors.
